R&D 100 Award Goes to Waters ionKey/MS System
November 16 2015 - 4:12PM
Business Wire
Novel Approach is Enhancing the Sensitivity of
Bioanalytical, Biomarker Validation, Pharmacokinetic and Food
Research LC/MS Analyses
Waters Corporation (NYSE:WAT) today announced that the Waters®
ionKey/MS™ System has received an R&D Magazine R&D 100
Award as one of the 100 most technologically innovative products to
be introduced over the past year.
“I’d like to thank the publisher and editors of R&D Magazine
and the judges for choosing our ionKey/MS System for this award,”
said Ian King, Vice President – Separations Science, Waters
Division. “The response of scientists to the product has been
extremely gratifying and our development team and our collaborators
deserve all the credit for bringing this product to market despite
the technological challenges this novel approach presented.”
Intended for use with Waters ACQUITY® UPLC® M-Class System and a
range of Waters mass spectrometers, including the Xevo® TQ-S , Xevo
G2-XS and the Synapt® G2-Si, the Waters ionKey/MS System physically
integrates a UPLC separation into the mass spectrometer producing
up to a 40x improvement in sensitivity, enabling scientists to
achieve unparalleled separation and detection of compounds. The
ionKey/MS System’s iKey Microfluidic Separation Device, which is
about the size of a smart phone, contains the fluidic connections,
electronics, ESI interface, column heater, eCord™ Intelligent Chip
Technology and the 1.7 micron UPLC grade particles packed inside a
150 micron I.D. channel to perform hundreds upon hundreds of UPLC
separations reproducibly and reliably without a degradation in
performance.
For quantifying extremely low abundant analytes, researchers
often turn to microscale LC techniques employing microfluidics
because of their ability to optimize ionization efficiency and
improve MS sampling. In their 2014 article in the journal
Bioanalysis, Merck scientists beta-testing the ionKey/MS System
reported that the method they developed achieved an overall 20-fold
increase in sensitivity (0.5 picomoles vs. 11 picomoles) for
endogenous levels of GLP-1 in human plasma, a faster run time (nine
minutes vs. 35 minutes), increased specificity and resolution over
a more traditional LC-MS/MS method.
Since the R&D 100 award competition began, Waters has won
nine R&D 100 awards, most recently for its CORTECS® 1.6 micron
analytical columns, Oasis® 96-Well (micro) Elution Extraction
Plate, XTERRA® Columns, ACQUITY UPLC System and the ACQUITY UPC2®
System.
For more information: www.waters.com/ionkey
About the R&D 100 Awards
Widely recognized as the “Oscars of Invention”, the R&D 100
Awards identify and celebrate the top technology products of the
year. Past winners have included sophisticated testing equipment,
innovative new materials, chemistry breakthroughs, biomedical
products, consumer items, and high-energy physics. The R&D 100
Awards spans industry, academia, and government-sponsored
research.
For more information www.rdmag.com
About Waters Corporation
(www.waters.com)
Waters Corporation (NYSE: WAT) develops and manufactures
advanced analytical and material science technologies for
laboratory dependent organizations. For more than 50 years, the
company has pioneered a connected portfolio of separations science,
laboratory information management, mass spectrometry and thermal
analysis systems.
Waters, XTERRA, Oasis, Xevo, eCord, Synapt, CORTECS, ACQUITY,
ACQUITY UPLC, ionKey/MS and UPLC are trademarks of Waters
Corporation.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151116006472/en/
Waters CorporationBrian J. Murphy, +1 508-482-2614Public
Relations Managerbrian_j_murphy@waters.com
Waters (NYSE:WAT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Waters (NYSE:WAT)
Historical Stock Chart
From Apr 2023 to Apr 2024